SCHEMBL21584043

SCHEMBL21584043

O=C1NCCOc2ccsc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP6 P51161 1/20 0.45
ACE2 Q9BYF1 1/20 0.35
GAA P10253 3/20 0.35
ALDH1A1 P00352 2/20 0.35
HSD17B10 Q99714 2/20 0.35
MAPT P10636 1/20 0.35
KDM4E B2RXH2 2/20 0.34
GLA P06280 1/20 0.34
HPGD P15428 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
ATM Q13315 1/20 0.34
GSK3B P49841 3/20 0.33
MAP3K14 Q99558 1/20 0.33
NTRK1 P04629 2/20 0.33
PIM1 P11309 2/20 0.33
CHEK1 O14757 1/20 0.33
AURKA O14965 1/20 0.33
DAPK3 O43293 1/20 0.33
PRKD3 O94806 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26970887 0.83 ACE2 (0.38) ACE2CES1NOS3NOS2NOS1
SCHEMBL20561610 0.73 ITGB2 (0.41) GAAALDH1A1HPGDMAP3K14DYRK1A
SCHEMBL11977442 0.73
SCHEMBL8069167 0.72 MAP3K14 (0.41) ALDH1A1HPGDMAP3K14CLK2DYRK1A
SCHEMBL25220853 0.71 FABP6 (0.45) FABP6KDM4EGSK3BLTKCDK5
SCHEMBL504352 0.69 GSK3B (0.40) GAAALDH1A1HSD17B10HPGDCASP1
SCHEMBL29960501 0.69 MAP3K14 (0.36) ACE2MAPTHPGDMAP3K14DYRK1A
SCHEMBL3974015 0.69 TSHR (0.38) GAAALDH1A1MAPTKDM4EHPGD
SCHEMBL390083 0.68 PARP10 (0.46) KDM4ECHEK1CES1NOS3NOS2
SCHEMBL352852 0.67 FABP6 (0.60) FABP6ALDH1A1KDM4EGSK3BNTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630561-B2 Tricyclic derivatives inhibitor, preparation method, and applications thereof JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2026-05-19 US disclosed
EP-3805231-B1 INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD (CN) 2024-10-16 EP disclosed
CN-114835729-B Inhibitor containing tricyclic derivatives, preparation method and application thereof 江苏豪森药业集团有限公司 2024-05-31 CN disclosed
CN-114835729-A Tricyclic derivative inhibitor, preparation method and application thereof 江苏豪森药业集团有限公司 2022-08-02 CN disclosed
CN-110785423-B Tricyclic derivative inhibitor, preparation method and application thereof 江苏豪森药业集团有限公司 2022-07-26 CN disclosed
US-20210221822-A1 TRICYCLIC DERIVATIVES INHIBITOR, PREPARATION METHOD, AND APPLICATIONS THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2021-07-22 US disclosed
US-20210221822-A1 TRICYCLIC DERIVATIVES INHIBITOR, PREPARATION METHOD, AND APPLICATIONS THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2021-07-22 US disclosed
EP-3805231-A1 INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) 2021-04-14 EP disclosed
EP-3805231-A1 INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) 2021-04-14 EP disclosed
CN-110785423-A Tricyclic derivative inhibitor, preparation method and application thereof 江苏豪森药业集团有限公司 2020-02-11 CN disclosed
WO-2019228341-A1 INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 江苏豪森药业集团有限公司 (CN) 2019-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210221822-A1 TRICYCLIC DERIVATIVES INHIBITOR, PREPARATION METHOD, AND APPLICATIONS THEREOF PIK3CA, PIK3CD, PIK3CB FABP6 4091/4885ACE2 3767/4885GAA 747/4885
US-12630561-B2 Tricyclic derivatives inhibitor, preparation method, and applications thereof PIK3CA, PIK3R1, PIK3CD FABP6 3860/4885ACE2 3151/4885GAA 2153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.